Rezolute Inc RZLT
News
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute to Participate in Upcoming Investor Conferences
Rezolute Application for Hypoglycemia Treatment Gets FDA Clearance
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Rezolute to Participate in the BTIG Virtual Biotechnology Conference